Foghorn Therapeuticsinc Stock Analysis

FHTX Stock  USD 6.71  0.43  6.85%   
Foghorn TherapeuticsInc is undervalued with Real Value of 8.45 and Target Price of 15.25. The main objective of Foghorn TherapeuticsInc stock analysis is to determine its intrinsic value, which is an estimate of what Foghorn TherapeuticsInc is worth, separate from its market price. There are two main types of Foghorn TherapeuticsInc's stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect Foghorn TherapeuticsInc's performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of Foghorn TherapeuticsInc's stock to identify patterns and trends that may indicate its future price movements.
The Foghorn TherapeuticsInc stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Foghorn TherapeuticsInc is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Foghorn Stock trading window is adjusted to America/New York timezone. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Foghorn TherapeuticsInc's ongoing operational relationships across important fundamental and technical indicators.
  
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Foghorn TherapeuticsInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.
For more information on how to buy Foghorn Stock please use our How to Invest in Foghorn TherapeuticsInc guide.

Foghorn Stock Analysis Notes

About 25.0% of the company shares are held by company insiders. The company recorded a loss per share of 2.34. Foghorn TherapeuticsInc had not issued any dividends in recent years. Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Foghorn Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 119 people. To learn more about Foghorn TherapeuticsInc call Adrian Gottschalk at 617 586 3100 or check out https://foghorntx.com.

Foghorn TherapeuticsInc Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Foghorn TherapeuticsInc's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Foghorn TherapeuticsInc or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Foghorn TherapeuticsInc is way too risky over 90 days horizon
Foghorn TherapeuticsInc appears to be risky and price may revert if volatility continues
The company reported the previous year's revenue of 34.16 M. Net Loss for the year was (98.43 M) with loss before overhead, payroll, taxes, and interest of (86.39 M).
Foghorn TherapeuticsInc currently holds about 373.5 M in cash with (118.11 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.94, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Roughly 62.0% of the company shares are owned by institutional investors
Latest headline from investing.com: Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting

Foghorn TherapeuticsInc Upcoming and Recent Events

Earnings reports are used by Foghorn TherapeuticsInc to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Foghorn TherapeuticsInc previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
14th of March 2024
Upcoming Quarterly Report
View
13th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
14th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Foghorn Largest EPS Surprises

Earnings surprises can significantly impact Foghorn TherapeuticsInc's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2023-03-09
2022-12-31-0.62-0.69-0.0711 
2022-08-09
2022-06-30-0.59-0.66-0.0711 
2022-05-09
2022-03-31-0.52-0.65-0.1325 
View All Earnings Estimates

Foghorn Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Foghorn TherapeuticsInc is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Foghorn TherapeuticsInc backward and forwards among themselves. Foghorn TherapeuticsInc's institutional investor refers to the entity that pools money to purchase Foghorn TherapeuticsInc's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Driehaus Capital Management Llc2023-12-31
343.7 K
Birchview Capital, Lp2023-12-31
320.9 K
Point72 Asset Management, L.p.2023-09-30
284.9 K
Northern Trust Corp2023-12-31
199.3 K
Sio Capital Management, Llc2023-12-31
121.7 K
Morgan Stanley - Brokerage Accounts2023-12-31
105.1 K
Panagora Asset Management Inc2023-12-31
97 K
Bank Of New York Mellon Corp2023-12-31
57.2 K
Charles Schwab Investment Management Inc2023-12-31
55.4 K
Flagship Ventures Management, Inc.2023-09-30
12.7 M
Fmr Inc2023-12-31
2.8 M
Note, although Foghorn TherapeuticsInc's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Foghorn Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 283.02 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Foghorn TherapeuticsInc's market, we take the total number of its shares issued and multiply it by Foghorn TherapeuticsInc's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Foghorn Profitablity

Foghorn TherapeuticsInc's profitability indicators refer to fundamental financial ratios that showcase Foghorn TherapeuticsInc's ability to generate income relative to its revenue or operating costs. If, let's say, Foghorn TherapeuticsInc is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Foghorn TherapeuticsInc's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Foghorn TherapeuticsInc's profitability requires more research than a typical breakdown of Foghorn TherapeuticsInc's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (2.88) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (4.41) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $4.41.
Last ReportedProjected for 2024
Return On Capital Employed(0.47)(0.50)
Return On Assets(0.34)(0.36)
Return On Equity 1.28  1.34 

Management Efficiency

Foghorn TherapeuticsInc has return on total asset (ROA) of (0.1953) % which means that it has lost $0.1953 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (4.7038) %, meaning that it created substantial loss on money invested by shareholders. Foghorn TherapeuticsInc's management efficiency ratios could be used to measure how well Foghorn TherapeuticsInc manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to rise to 1.34 in 2024, whereas Return On Capital Employed is likely to drop (0.50) in 2024. At this time, Foghorn TherapeuticsInc's Fixed Asset Turnover is fairly stable compared to the past year. Asset Turnover is likely to rise to 0.13 in 2024, whereas Total Assets are likely to drop slightly above 280.8 M in 2024.
Last ReportedProjected for 2024
Price Book Value Ratio(3.51)(3.33)
Enterprise Value Multiple(2.37)(2.49)
Price Fair Value(3.51)(3.33)
The analysis of Foghorn TherapeuticsInc's management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Foghorn TherapeuticsInc's future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Foghorn Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Beta
3.167

Technical Drivers

As of the 29th of March, Foghorn TherapeuticsInc shows the Mean Deviation of 6.29, downside deviation of 6.77, and Coefficient Of Variation of 2284.67. Foghorn TherapeuticsInc technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate and analyze data for nineteen technical drivers for Foghorn TherapeuticsInc, which can be compared to its rivals. Please confirm Foghorn TherapeuticsInc mean deviation, information ratio, as well as the relationship between the Information Ratio and downside variance to decide if Foghorn TherapeuticsInc is priced favorably, providing market reflects its regular price of 6.71 per share. Given that Foghorn TherapeuticsInc has jensen alpha of (0.03), we urge you to verify Foghorn TherapeuticsInc's prevailing market performance to make sure the company can sustain itself at a future point.

Foghorn TherapeuticsInc Price Movement Analysis

Execute Study
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Foghorn TherapeuticsInc middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Foghorn TherapeuticsInc. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Foghorn TherapeuticsInc Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Foghorn TherapeuticsInc insiders, such as employees or executives, is commonly permitted as long as it does not rely on Foghorn TherapeuticsInc's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Foghorn TherapeuticsInc insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Foghorn TherapeuticsInc Predictive Daily Indicators

Foghorn TherapeuticsInc intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Foghorn TherapeuticsInc stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Foghorn TherapeuticsInc Corporate Filings

F4
12th of March 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
10K
7th of March 2024
Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance
ViewVerify
13A
9th of February 2024
An amended filing to the original Schedule 13G
ViewVerify
8K
8th of February 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
F4
25th of January 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F4
17th of January 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
8K
8th of January 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
8K
3rd of January 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify

Foghorn TherapeuticsInc Forecast Models

Foghorn TherapeuticsInc's time-series forecasting models are one of many Foghorn TherapeuticsInc's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Foghorn TherapeuticsInc's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Foghorn Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Foghorn TherapeuticsInc prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Foghorn shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Foghorn TherapeuticsInc. By using and applying Foghorn Stock analysis, traders can create a robust methodology for identifying Foghorn entry and exit points for their positions.
Last ReportedProjected for 2024
Pretax Profit Margin(2.76)(2.90)
Operating Profit Margin(3.16)(3.32)
Net Loss(2.88)(3.03)
Gross Profit Margin 0.75  0.78 

Current Foghorn Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Foghorn analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Foghorn analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
15.25Strong Buy5Odds
Foghorn TherapeuticsInc current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Foghorn analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Foghorn stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Foghorn TherapeuticsInc, talking to its executives and customers, or listening to Foghorn conference calls.
Foghorn Analyst Advice Details

Foghorn Stock Analysis Indicators

Foghorn TherapeuticsInc stock analysis indicators help investors evaluate how Foghorn TherapeuticsInc stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Foghorn TherapeuticsInc shares will generate the highest return on investment. By understating and applying Foghorn TherapeuticsInc stock analysis, traders can identify Foghorn TherapeuticsInc position entry and exit signals to maximize returns.
Begin Period Cash Flow52.2 M
Common Stock Shares Outstanding42 M
Total Stockholder Equity-77.2 M
Tax Provision4.2 M
Property Plant And Equipment Net42.9 M
Cash And Short Term Investments234.1 M
Cash80.3 M
Accounts Payable6.3 M
Net Debt-35.3 M
50 Day M A5.5038
Total Current Liabilities58.4 M
Other Operating Expenses142.1 M
Non Current Assets Total45.7 M
Non Currrent Assets Other1.1 M
Stock Based Compensation16.2 M
When determining whether Foghorn TherapeuticsInc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Foghorn TherapeuticsInc's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Foghorn Therapeuticsinc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Foghorn Therapeuticsinc Stock:
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Foghorn TherapeuticsInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.
For more information on how to buy Foghorn Stock please use our How to Invest in Foghorn TherapeuticsInc guide.
You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.

Complementary Tools for Foghorn Stock analysis

When running Foghorn TherapeuticsInc's price analysis, check to measure Foghorn TherapeuticsInc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Foghorn TherapeuticsInc is operating at the current time. Most of Foghorn TherapeuticsInc's value examination focuses on studying past and present price action to predict the probability of Foghorn TherapeuticsInc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Foghorn TherapeuticsInc's price. Additionally, you may evaluate how the addition of Foghorn TherapeuticsInc to your portfolios can decrease your overall portfolio volatility.
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Fundamental Analysis
View fundamental data based on most recent published financial statements
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Is Foghorn TherapeuticsInc's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Foghorn TherapeuticsInc. If investors know Foghorn will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Foghorn TherapeuticsInc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.34)
Revenue Per Share
0.814
Quarterly Revenue Growth
0.379
Return On Assets
(0.20)
Return On Equity
(4.70)
The market value of Foghorn TherapeuticsInc is measured differently than its book value, which is the value of Foghorn that is recorded on the company's balance sheet. Investors also form their own opinion of Foghorn TherapeuticsInc's value that differs from its market value or its book value, called intrinsic value, which is Foghorn TherapeuticsInc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Foghorn TherapeuticsInc's market value can be influenced by many factors that don't directly affect Foghorn TherapeuticsInc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Foghorn TherapeuticsInc's value and its price as these two are different measures arrived at by different means. Investors typically determine if Foghorn TherapeuticsInc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Foghorn TherapeuticsInc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.